Newsletter Tool

Today’s Big News

Jul 1, 2024

BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy

Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24

J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

Lilly signs $140M upfront partnership with Radionetics in latest radiopharma play

Merck & Co. opts in on Orion's hormone-dependent cancer candidates

No CRISPR, no problem: 'Jumping gene' system could be bridge to complex gene editing

Featured

BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

By Nick Paul Taylor

Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push.

Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy

By James Waldron

Artiva Biotherapeutics has become the latest biotech to set out IPO ambitions for the summer, as the allogeneic natural killer cell therapy company pushes its lead program through automimmune clinical trials.

Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24

By Annalee Armstrong

The slow quarter follows an exciting first one, in which pharma finally spent some of the trillions in cash hanging around for such transactions.

J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

By Nick Paul Taylor

Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis, providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB.

Lilly signs $140M upfront partnership with Radionetics in latest radiopharma play

By James Waldron

Eli Lilly is continuing to pursue its newfound passion for radiopharmaceuticals, this time handing Radionetics Oncology $140 million in upfront cash to partner on its pipeline of G protein coupled receptor (GPCR) targeted drugs.

Merck & Co. opts in on Orion's hormone-dependent cancer candidates

By Gabrielle Masson

Merck & Co. is expanding a research partnership with Orion into an exclusive licensing pact, putting more than $1.6 billion biobucks on the table for cancer candidates targeting CYP11A1, an enzyme important in steroid production.

No CRISPR, no problem: 'Jumping gene' system could be bridge to complex gene editing

By Helen Floersh

A new gene editing technique derived from bacterial “jumping genes” can add, remove, recombine and invert DNA sequences, potentially overcoming some of the limitations of CRISPR.

Pfizer poaches Novartis exec to succeed retiring Suneet Varma as oncology commercial chief

By Angus Liu

Pfizer has hired a new oncology commercialization leader from its rival Novartis to help the business reach its goal of marketing eight blockbuster drugs by 2030.

FDA commissioner heralds end to US shortfall of chemo drug cisplatin

By Joseph Keenan

Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said.

Justice Department charges 193 defendants for $2.8B of healthcare fraud

By Dave Muoio

The cases highlighted by law enforcement involved medically unnecessary amniotic wound grafts, diverted HIV medications, online distribution of Adderall and other telemedicine schemes.

Fierce podcasts

Don’t miss an episode

The best biopharma M&A deals

In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.

LGBTQ+ fertility and family building

A closer look at 'friend-shoring' and the drug shortage challenge

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences